Literature DB >> 8416382

The cytoplasmic domain of the human T-cell leukemia virus type I envelope can modulate envelope functions in a cell type-dependent manner.

C Pique1, D Pham, T Tursz, M C Dokhélar.   

Abstract

C-terminal truncations of the human T-cell leukemia virus type I envelope affected the intracellular maturation and syncytium formation in a cell type-dependent manner. The intracytoplasmic domain appears dispensable for syncytium formation, but its truncation can modulate the envelope functionality in some cell types.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8416382      PMCID： PMC237394     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  31 in total

1.  The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.

Authors:  X Yu; X Yuan; Z Matsuda; T H Lee; M Essex
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome.

Authors:  C B Lozzio; B B Lozzio
Journal:  Blood       Date:  1975-03       Impact factor: 22.113

3.  Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of the HIV-1 envelope protein.

Authors:  M Autiero; P Abrescia; M Dettin; C Di Bello; J Guardiola
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

4.  Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity.

Authors:  K A Page; S M Stearns; D R Littman
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Cytoplasmic domain truncation enhances fusion activity by the exterior glycoprotein complex of human immunodeficiency virus type 2 in selected cell types.

Authors:  M J Mulligan; G V Yamshchikov; G D Ritter; F Gao; M J Jin; C D Nail; C P Spies; B H Hahn; R W Compans
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

6.  SV40-transformed simian cells support the replication of early SV40 mutants.

Authors:  Y Gluzman
Journal:  Cell       Date:  1981-01       Impact factor: 41.582

7.  A monoclonal antibody with anti-Burkitt lymphoma specificity. I. Analysis of human haematopoietic and lymphoid cell lines.

Authors:  J Wiels; G M Lenoir; M Fellous; M Lipinski; J C Salomon; C Tetaud; T Tursz
Journal:  Int J Cancer       Date:  1982-06-15       Impact factor: 7.396

8.  Interleukin 1 (IL 1)-dependent lymphokine production by human leukemic T cell line HSB.2 subclones.

Authors:  T Kasahara; N Mukaida; K Hatake; K Motoyoshi; T Kawai; K Shiori-Nakano
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

9.  Demonstration of the absence of infectious Rous virus in rat tumour XC, whose structurally intact cells produce Rous sarcoma when transferred to chicks.

Authors:  J SVOBODA; P CHYLE; D SIMKOVIC; I HILGERT
Journal:  Folia Biol (Praha)       Date:  1963-04       Impact factor: 0.906

10.  Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA.

Authors:  M Seiki; S Hattori; Y Hirayama; M Yoshida
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205
View more
  18 in total

1.  Identification of two intracellular mechanisms leading to reduced expression of oncoretrovirus envelope glycoproteins at the cell surface.

Authors:  M P Grange; V Blot; L Delamarre; I Bouchaert; A Rocca; A Dautry-Varsat; M C Dokhélar
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  The ectodomain of the human T-cell leukemia virus type 1 TM glycoprotein is involved in postfusion events.

Authors:  A R Rosenberg; L Delamarre; C Pique; D Pham; M C Dokhélar
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Two distinct oncornaviruses harbor an intracytoplasmic tyrosine-based basolateral targeting signal in their viral envelope glycoprotein.

Authors:  R Lodge; L Delamarre; J P Lalonde; J Alvarado; D A Sanders; M C Dokhélar; E A Cohen; G Lemay
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity.

Authors:  B A Brody; S S Rhee; E Hunter
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

5.  Similar regulation of cell surface human T-cell leukemia virus type 1 (HTLV-1) surface binding proteins in cells highly and poorly transduced by HTLV-1-pseudotyped virions.

Authors:  Kathryn S Jones; Manisha Nath; Cari Petrow-Sadowski; Andrea C Baines; Megan Dambach; Ying Huang; Francis W Ruscetti
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

6.  Human T-cell leukemia virus type 1 receptor expression among syncytium-resistant cell lines revealed by a novel surface glycoprotein-immunoadhesin.

Authors:  S R Jassal; R G Pöhler; D W Brighty
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

7.  Identification of functional regions in the human T-cell leukemia virus type I SU glycoprotein.

Authors:  L Delamarre; C Pique; D Pham; T Tursz; M C Dokhélar
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

8.  Relationship between SU subdomains that regulate the receptor-mediated transition from the native (fusion-inhibited) to the fusion-active conformation of the murine leukemia virus glycoprotein.

Authors:  Dimitri Lavillette; Alessia Ruggieri; Bertrand Boson; Marielle Maurice; François-Loïc Cosset
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Identification and mapping of functional domains on human T-cell lymphotropic virus type 1 envelope proteins by using synthetic peptides.

Authors:  Y Sagara; Y Inoue; H Shiraki; A Jinno; H Hoshino; Y Maeda
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

10.  Influence of transmembrane domains on the fusogenic abilities of human and murine leukemia retrovirus envelopes.

Authors:  C Denesvre; P Sonigo; A Corbin; H Ellerbrok; M Sitbon
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.